Published in Oncoimmunology on October 21, 2013
Classification of current anticancer immunotherapies. Oncotarget (2014) 1.55
Trial Watch: Toll-like receptor agonists in oncological indications. Oncoimmunology (2014) 0.96
First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology (2015) 0.88
Dendritic Cell Therapy in an Allogeneic-Hematopoietic Cell Transplantation Setting: An Effective Strategy toward Better Disease Control? Front Immunol (2014) 0.86
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8(+) T-cell response, prominent infiltration of CD8(+) lymphocytes and Th1 type polarization. Oncoimmunology (2014) 0.85
Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer (2016) 0.85
Tissue-resident dendritic cells and diseases involving dendritic cell malfunction. Int Immunopharmacol (2016) 0.80
Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma. Immunol Res (2014) 0.78
Proof of concept study with an HER-2 mimotope anticancer vaccine deduced from a novel AAV-mimotope library platform. Oncoimmunology (2016) 0.76
Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8(+) effector T cell responses. Oncoimmunology (2016) 0.75
N-Dihydrogalactochitosan as a potent immune activator for dendritic cells. J Biomed Mater Res A (2016) 0.75
Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment. Cancer Immunol Immunother (2015) 0.75
IgE immunotherapy against cancer. Curr Top Microbiol Immunol (2015) 0.75
Mulberry leaf polysaccharides modulate murine bone-marrow-derived dendritic cell maturation. Hum Vaccin Immunother (2015) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer (1972) 35.74
Cell death: the significance of apoptosis. Int Rev Cytol (1980) 24.88
Immunobiology of dendritic cells. Annu Rev Immunol (2000) 23.65
Release of chromatin protein HMGB1 by necrotic cells triggers inflammation. Nature (2002) 19.77
In vivo depletion of CD11c+ dendritic cells abrogates priming of CD8+ T cells by exogenous cell-associated antigens. Immunity (2002) 14.57
Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2006) 10.54
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature (1998) 9.77
Molecular mechanisms of necroptosis: an ordered cellular explosion. Nat Rev Mol Cell Biol (2010) 9.06
Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med (2009) 6.73
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med (2000) 5.62
NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell (2006) 5.35
Death by design: apoptosis, necrosis and autophagy. Curr Opin Cell Biol (2004) 5.31
The CD8+ dendritic cell subset selectively endocytoses dying cells in culture and in vivo. J Exp Med (2002) 4.78
Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-kappa B pathway. Int Immunol (2000) 4.48
Immunogenic and tolerogenic cell death. Nat Rev Immunol (2009) 4.34
Deciphering the transcriptional network of the dendritic cell lineage. Nat Immunol (2012) 4.17
Human CD141+ (BDCA-3)+ dendritic cells (DCs) represent a unique myeloid DC subset that cross-presents necrotic cell antigens. J Exp Med (2010) 4.17
Differential lysosomal proteolysis in antigen-presenting cells determines antigen fate. Science (2005) 4.12
Cross-presentation by dendritic cells. Nat Rev Immunol (2012) 3.95
Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. Nature (2009) 3.93
Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med (2011) 3.85
Ligands for clathrin-mediated endocytosis are differentially sorted into distinct populations of early endosomes. Cell (2006) 3.83
Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer (2012) 3.76
Distinct pathways of antigen uptake and intracellular routing in CD4 and CD8 T cell activation. Science (2007) 3.27
Tumor therapy in mice via antigen targeting to a novel, DC-restricted C-type lectin. J Clin Invest (2008) 3.14
Microtubule-associated protein 1 light chain 3 alpha (LC3)-associated phagocytosis is required for the efficient clearance of dead cells. Proc Natl Acad Sci U S A (2011) 3.11
HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep (2004) 3.00
The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev (2007) 2.96
Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts. J Biol Chem (2001) 2.74
Rab27a regulates phagosomal pH and NADPH oxidase recruitment to dendritic cell phagosomes. Nat Cell Biol (2007) 2.69
Noncanonical autophagy is required for type I interferon secretion in response to DNA-immune complexes. Immunity (2012) 2.69
NADPH oxidase controls phagosomal pH and antigen cross-presentation in human dendritic cells. Blood (2008) 2.54
CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3+ dendritic cells and a subset of monocytes. J Biol Chem (2008) 2.34
Cell death: apoptosis versus necrosis (review). Int J Oncol (2002) 2.20
The mannose receptor mediates uptake of soluble but not of cell-associated antigen for cross-presentation. J Immunol (2006) 2.09
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8+ T cells in a spectrum of human MHC I haplotypes. Proc Natl Acad Sci U S A (2007) 2.04
CD103+ pulmonary dendritic cells preferentially acquire and present apoptotic cell-associated antigen. J Exp Med (2011) 1.95
The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. Immunity (2012) 1.89
Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol (1999) 1.82
Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res (2001) 1.82
Efficient T cell activation via a Toll-Interleukin 1 Receptor-independent pathway. Immunity (2006) 1.78
Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity. J Immunother (2006) 1.75
Cross-presentation of cell-associated antigens by CD8alpha+ dendritic cells is attributable to their ability to internalize dead cells. Immunology (2002) 1.72
The dendritic cell receptor DNGR-1 controls endocytic handling of necrotic cell antigens to favor cross-priming of CTLs in virus-infected mice. J Clin Invest (2012) 1.69
Antigen-antibody immune complexes empower dendritic cells to efficiently prime specific CD8+ CTL responses in vivo. J Immunol (2002) 1.66
Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells. Cell Death Differ (2009) 1.62
Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies. Hum Immunol (1999) 1.57
Effective induction of naive and recall T-cell responses by targeting antigen to human dendritic cells via a humanized anti-DC-SIGN antibody. Blood (2005) 1.57
Secondary necrosis: the natural outcome of the complete apoptotic program. FEBS Lett (2010) 1.57
The small GTPase Rac2 controls phagosomal alkalinization and antigen crosspresentation selectively in CD8(+) dendritic cells. Immunity (2009) 1.53
Found in translation: the human equivalent of mouse CD8+ dendritic cells. J Exp Med (2010) 1.45
TLR agonists stimulate Nlrp3-dependent IL-1β production independently of the purinergic P2X7 receptor in dendritic cells and in vivo. J Immunol (2012) 1.42
Similar antigen cross-presentation capacity and phagocytic functions in all freshly isolated human lymphoid organ-resident dendritic cells. J Exp Med (2013) 1.40
Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci (2013) 1.34
Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. J Biol Chem (2007) 1.33
The role of heat shock proteins in antigen cross presentation. Front Immunol (2012) 1.33
Human dendritic cell deficiency: the missing ID? Nat Rev Immunol (2011) 1.32
Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int J Cancer (2003) 1.32
Generation of tumor-specific T-lymphocytes by cross-priming with human dendritic cells ingesting apoptotic tumor cells. Cancer Res (2000) 1.30
Characterization of the MHC class I cross-presentation pathway for cell-associated antigens by human dendritic cells. Blood (2003) 1.29
Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res (2001) 1.24
Antigen storage compartments in mature dendritic cells facilitate prolonged cytotoxic T lymphocyte cross-priming capacity. Proc Natl Acad Sci U S A (2009) 1.24
Progress in the development of immunotherapy for the treatment of patients with cancer. J Intern Med (2001) 1.20
Efficient cross-presentation by heat shock protein 90-peptide complex-loaded dendritic cells via an endosomal pathway. J Immunol (2007) 1.18
Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate. Cancer Immunol Immunother (2005) 1.16
Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res (2002) 1.09
Development of antigen cross-presentation capacity in dendritic cells. Trends Immunol (2012) 1.08
Apoptotic pancreatic tumor cells are superior to cell lysates in promoting cross-priming of cytotoxic T cells and activate NK and gammadelta T cells. Cancer Res (2002) 1.08
IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing. Blood (2011) 1.07
Antigen cross-presentation by dendritic cell subsets: one general or all sergeants? Trends Immunol (2013) 1.05
CD40-CD40Ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol (1998) 1.04
Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming. J Immunol (2011) 1.04
Direct antigen presentation and gap junction mediated cross-presentation during apoptosis. J Immunol (2009) 1.03
Immune adjuvant efficacy of CpG oligonucleotide in cancer treatment is founded specifically upon TLR9 function in plasmacytoid dendritic cells. Cancer Res (2011) 1.03
Fcγ receptor antigen targeting potentiates cross-presentation by human blood and lymphoid tissue BDCA-3+ dendritic cells. Blood (2012) 1.01
Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory. Cancer Immun (2003) 0.99
Phases of apoptosis of melanoma cells, but not of normal melanocytes, differently affect maturation of myeloid dendritic cells. Cancer Res (2001) 0.98
Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res (1999) 0.98
Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine (2008) 0.96
Drug- and cell-mediated antitumor cytotoxicities modulate cross-presentation of tumor antigens by myeloid dendritic cells. Anticancer Drugs (2003) 0.93
NADPH oxidases contribute to autophagy regulation. Autophagy (2009) 0.93
A critical role for granzymes in antigen cross-presentation through regulating phagocytosis of killed tumor cells. J Immunol (2011) 0.92
Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity. Immunol Lett (2002) 0.91
Prolonged antigen storage endows merocytic dendritic cells with enhanced capacity to prime anti-tumor responses in tumor-bearing mice. J Immunol (2010) 0.90
Influence of drug-induced apoptotic death on processing and presentation of tumor antigens by dendritic cells. Int J Cancer (2003) 0.90
Invariant NKT cells induce plasmacytoid dendritic cell (DC) cross-talk with conventional DCs for efficient memory CD8+ T cell induction. J Immunol (2013) 0.88
Induction of type I IFN is a physiological immune reaction to apoptotic cell-derived membrane microparticles. J Immunol (2012) 0.87
Antigen persistence is required for dendritic cell licensing and CD8+ T cell cross-priming. J Immunol (2008) 0.87
Forced expression of heat-shock protein 70 increases the secretion of Hsp70 and provides protection against tumour growth. Br J Cancer (2004) 0.86
Purified apoptotic bodies stimulate plasmacytoid dendritic cells to produce IFN-alpha. Autoimmunity (2007) 0.85
Dendritic cells efficiently cross-prime HLA class I-restricted cytolytic T lymphocytes when pulsed with both apoptotic and necrotic cells but not with soluble cell-derived lysates. Int Immunol (2000) 0.85
Increased immunogenicity of colon cancer cells by selective depletion of cytochrome C. Cancer Res (2004) 0.82
Cross-presentation of NY-ESO-1 cytotoxic T lymphocyte epitope fused to human heat shock cognate protein 70 by dendritic cells. Cancer Sci (2007) 0.81
Mechanism of dichotomy between CD8+ responses elicited by apoptotic and necrotic cells. Cancer Immun (2013) 0.80
Primary sterile necrotic cells fail to cross-prime CD8(+) T cells. Oncoimmunology (2012) 0.78
Whole lymphoma B cells allow efficient cross-presentation of antigens by dendritic cells. Cytotherapy (2008) 0.78
Assessment of roles for calreticulin in the cross-presentation of soluble and bead-associated antigens. PLoS One (2012) 0.76